Stocktoria
BELITE BIO, INC BLTE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-04-29
BELITE BIO, INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $45.4M | $29.9M | $24.8M | $8.9M | $7.4M |
| SG&A expense | $38.8M | $10.1M | $6.8M | — | — |
| Operating income | -$84.2M | -$40.0M | -$31.7M | -$12.8M | -$9.8M |
| Interest expense | — | — | $25,000 | $16,000 | — |
| Income tax | $0 | $6,000 | $9,000 | — | — |
| Net income | -$77.6M | -$36.1M | -$31.6M | -$12.6M | -$9.7M |
| EPS (diluted) | $-2.31 | $-1.18 | $-1.19 | $-0.63 | $-1.01 |
| Operating cash flow | -$37.0M | -$29.2M | -$29.8M | -$11.5M | -$7.5M |
| Free cash flow | -$37.1M | -$29.4M | -$29.9M | -$11.9M | -$7.5M |
| Cash & equivalents | $352.9M | $31.7M | $88.2M | $42.1M | $17.3M |
| Total assets | $780.6M | $152.1M | $94.6M | $44.3M | $18.3M |
| Total liabilities | $10.1M | $6.3M | $4.2M | $2.8M | $1.6M |
| Shareholders' equity | $770.5M | $145.8M | $90.4M | $41.5M | -$15.1M |
Source: SEC EDGAR filings · CIK 0001889109 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.